Brief: Chemomab Therapeutics Presents Data Reinforcing Clinical Potential Of CM-101
26/06/2023 12:57
June 26 (Reuters) - Chemomab Therapeutics Ltd CMMB.O :
* CHEMOMAB THERAPEUTICS PRESENTS DATA REINFORCING THE
CLINICAL
POTENTIAL OF CM-101 AS A NOVEL TREATMENT FOR PRIMARY SCLEROSING
CHOLANGITIS AT EASL 2023
Source text for Eikon: ID:nPn3p4vcNa
Further company coverage: CMMB.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Chemomab Therapeutics
See all newsBrief: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview
Israel's Chemomab Q4 net loss narrows on lower R&D spend
Brief: Chemomab Therapeutics Announces Nebokitug Phase 2 Spring Trial Results
Brief: Chemomab Therapeutics Announces Third Quarter 2025 Financial Results And Provides Corporate Update